Bryan Garnier - Media Analytics Corp (MEDA) MEDARTIS: Cutting our numbers following H1 2019 results | BUY | CHF64 vs. CHF74,5 (+44%)

Report

Bryan Garnier

Hugo Solvet

MEDARTIS: Cutting our numbers following H1 2019 results | BUY | CHF64 vs. CHF74,5 (+44%)

MEDARTIS - BUY | CHF64 vs. CHF74,5 (+44%)
Cutting our numbers following H1 2019 results

Uncertainties ahead of EU MDR driving most of the downgrade
US set to accelerate in coming quarters
A hint to upcoming M&A?
Lower FV reflects FY19 guidance cut and weak EU until mid-2020

30/08/2019 3 EN

Underlying

Media Analytics Corp

See profile

US5843932014 Pink OTC Markets United States

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Hugo Solvet

Other Reports on these Companies

Independent Investment Research

Monthly LMI Update Independent Investment Research

Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked. This compares to the total dividends of 5 cents per share in FY20. The Board has confirmed that, in...

August 6, 2021 August 6, 2021 10 EN

Bryan Garnier

MEDARTIS: Remove Medartis from top picks after strong performance | BUY | CHF80(-11%)

MEDARTIS - BUY | CHF80(-11%) Remove Medartis from top picks after strong performance Medartis doubled YTD, and returned 28% since entering top picks Extremities still offers great growth to LT investors Largest opportunities still ahead Retain BUY TP CHF80, inorganic growth key catalyst for share

June 10, 2021 June 10, 2021 4 EN

Bryan Garnier

MEDARTIS: Reaching for the stars, in post-COVID extremities | BUY | CHF80 VS. 60(-2%)

MEDARTIS - BUY | CHF80 VS. 60(-2%) Reaching for the stars, in post-COVID extremities US strategy paying off KeriMedical allows Medartis to touch new markets More M&A on the agenda Update estimates TP EUR 80 (from EUR 60), retain BUY

March 30, 2021 March 30, 2021 3 EN

Adyen Q1 trading update offers no surprise

Adyen reported robust net revenue growth in Q1 2024 at +21% Y/Y, bang in line with market expectations. The unchanged guidance (low-to-high twenties' growth / >50% EBITDA margin in FY2026e) and macroeconomic environment do not call for an upward estimates revision: we stick to our +22% growth fo

9m 9m 1 EN

Aurelien Deside

Aurelien Deside

Rubrik IPO: unsustainable moat dictates sufficient margin of safety

Ahead of Rubrik's IPO later in the day, we review the vendor's activities, positioning, efficiency metrics, financials, and valuation. While we strongly believe in the growth of data security, we question Rubrik's ability to (profitably) differentiate itself over the long term, as both hyperscalers

15m 15m 1 EN

Clement Genelot

Clement Genelot

HelloFresh: Q1 marked by real dichotomy between ready-to-eat and meal-kit

Q1 slightly topped expectations thanks to ready-to-eat (+56% YoY) while meal-kit remained in the red (-7%) and lowered the group's EBITDA margin -250bp YoY. FY 2024 guidance has been reiterated, but we stay on the sidelines as we remain concerned by "meal-kit fatigue" longer-term implications for g

33m 33m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

MEDARTIS: Cutting our numbers following H1 2019 results | BUY | CHF64 vs. CHF74,5 (+44%)

Monthly LMI Update Independent Investment Research

MEDARTIS: Remove Medartis from top picks after strong performance | BUY | CHF80(-11%)

MEDARTIS: Reaching for the stars, in post-COVID extremities | BUY | CHF80 VS. 60(-2%)

Adyen Q1 trading update offers no surprise

Rubrik IPO: unsustainable moat dictates sufficient margin of safety

HelloFresh: Q1 marked by real dichotomy between ready-to-eat and meal-kit

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe